SeekingAlpha · Mar 6, 2026
RC
NASDAQ · RCKT
Rocket Pharmaceuticals, Inc.
Healthcare · Biotechnology
$2.56
Down-$0.07 (-2.66%)
Updated Oct 10, 2026, 4:26 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 372.83M
- P/E ratio
- -1.6
- Dividend yield
- 0.00%
- 52-week range
- $2.42 – $5.45
- Volume
- 3.37M
- Avg. volume
- 2.37M
Price performance · RCKT
RCKT price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
RCKT closed at $2.56 after 21 trading sessions, down 23.58% for the selected period.
- Last close
- $2.56
- Period change
- -23.58%
- Period low
- $2.48
- Period high
- $3.50
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $2.59 | $2.6883 | $2.54 | $2.56 | 3.37M |
| Oct 8, 2026 | $2.78 | $2.78 | $2.52 | $2.63 | 3.46M |
| Oct 7, 2026 | $2.45 | $2.64 | $2.42 | $2.535 | 2.81M |
| Oct 6, 2026 | $2.61 | $2.62 | $2.46 | $2.48 | 1.79M |
| Oct 5, 2026 | $2.59 | $2.63 | $2.50 | $2.61 | 1.66M |
| Oct 2, 2026 | $2.64 | $2.66 | $2.53 | $2.56 | 1.82M |
| Oct 1, 2026 | $2.62 | $2.745 | $2.58 | $2.59 | 2.09M |
| Sep 30, 2026 | $2.62 | $2.73 | $2.5501 | $2.63 | 2.53M |
| Sep 29, 2026 | $2.63 | $2.646 | $2.56 | $2.59 | 1.15M |
| Sep 28, 2026 | $2.57 | $2.62 | $2.51 | $2.61 | 2.08M |
| Sep 25, 2026 | $2.80 | $2.80 | $2.57 | $2.595 | 2.63M |
| Sep 24, 2026 | $3.00 | $3.025 | $2.66 | $2.69 | 4.38M |
| Sep 23, 2026 | $3.33 | $3.335 | $2.9525 | $3.02 | 2.78M |
| Sep 22, 2026 | $3.29 | $3.41 | $3.28 | $3.35 | 1.08M |
| Sep 21, 2026 | $3.40 | $3.405 | $3.265 | $3.27 | 1.36M |
| Sep 18, 2026 | $3.47 | $3.56 | $3.35 | $3.37 | 1.6M |
| Sep 17, 2026 | $3.59 | $3.755 | $3.48 | $3.50 | 1.86M |
| Sep 16, 2026 | $3.565 | $3.57 | $3.40 | $3.48 | 2.64M |
| Sep 15, 2026 | $3.65 | $3.685 | $3.21 | $3.41 | 3.66M |
| Sep 14, 2026 | $3.29 | $3.475 | $3.29 | $3.43 | 1.29M |
| Sep 11, 2026 | $3.52 | $3.52 | $3.25 | $3.35 | 1.66M |
Latest RCKT news
The latest Smart Investors Daily articles mentioning RCKT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RCKT research
Overview
Company profile and research snapshot.
Company profile
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | Goldman Sachs | Neutral | — |
| Oct 7, 2026 | Leerink Partners | Market Perform | — |
| Oct 7, 2026 | Wedbush | Outperform | — |
| Oct 7, 2026 | Chardan Capital | Buy | — |
| Sep 16, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 2, 2026
Goldman Sachs Maintains Sell on Rocket Pharmaceuticals, Raises Price Target to $3
Goldman Sachs analyst Richard Law maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Sell and raises the price target from $2 to $3.
Benzinga · Feb 27, 2026
Rocket Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 EPS results. Also, Cantor Fitzgerald raised its price target on the stock from $8 to $10.
Benzinga · Feb 27, 2026
Cantor Fitzgerald Maintains Overweight on Rocket Pharmaceuticals, Raises Price Target to $10
Cantor Fitzgerald analyst Josh Schimmer maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and raises the price target from $8 to $10.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
